Drug intelligence / Profile preview

Schmallenberg virus Gc subunit vaccine

Development stage
Unknown
Lead developer
Friedrich Loeffler Institute
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

A **veterinary recombinant protein subunit vaccine candidate** directed against **Schmallenberg virus**, built around the viral envelope glycoprotein **Gc**, particularly the immunogenic amino-terminal head or head-stalk region that contains major neutralizing epitopes. It was developed in preclinical research programs including groups at the Friedrich-Loeffler-Institut and collaborators as a **DIVA-compatible** alternative to whole-virus vaccines for preventing Schmallenberg virus infection and associated reproductive disease in ruminants such as cattle and sheep. The intended mechanism is induction of neutralizing anti-Gc antibodies that block viral entry and infection; published studies showed that some Gc-domain constructs could protect experimental animals, while other baculovirus-expressed Gc subunit formulations in cattle were immunogenic but did not reliably prevent viremia after challenge.

Other names
SBV Gc subunit vaccineSchmallenberg virus envelope glycoprotein Gc subunit vaccineGc AminoSchmallenberg virus Gc amino-terminal domain subunit vaccine
02

Targets

GC (Vitamin D-binding protein)

Beyond the preview

Go deeper on Schmallenberg virus Gc subunit vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Schmallenberg virus Gc subunit vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call